More News
8 October 2024
AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy2 October 2024
CAMP4 Enters Strategic Research Collaboration to Advance Novel Regulatory RNA-Targeting Medicines for Rare Genetic Conditions30 September 2024
Valerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based Therapeutics Company25 September 2024
Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI23 September 2024
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform18 September 2024
NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases18 September 2024
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%18 September 2024
Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million17 September 2024
Mindpeak Announces Collaboration With Roche to Enhance Cancer Diagnostics Through AI16 September 2024
Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected16 September 2024
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates16 September 2024
Linnaeus Therapeutics Announces Presentation of Positive Clinical Data of LNS8801 in Metastatic Melanoma at 2024 ESMO Annual Meeting10 September 2024
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies6 September 2024
Genetic Leap and Lilly Enter Collaboration to Accelerate Genetic Medicine Development with AI29 August 2024
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation26 August 2024
BPGbio to Present on its First-in-Class E2-based Approach to Targeted Protein Degradation at 15th Annual Drug Innovation Forum19 August 2024
Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports